Patrik Jeanmonod - 21 Feb 2023 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role: Chief Financial Officer
Signature: /s/ Valerie Barnett, Attorney-in-Fact for Patrik Jeanmonod
Issuer symbol: CTKB
Transactions as of: 21 Feb 2023
Net transactions value: -$7,493
Form type: 4
Filing time: 23 Feb 2023, 17:37:18 UTC
Previous filing: 25 Jan 2023
Next filing: 28 Feb 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CTKB	Common Stock	Options Exercise		+1,752	+1.5%		117,884	21 Feb 2023	Direct	F1
transaction	CTKB	Common Stock	Tax liability	$7,493	-683	-0.58%	$10.97	117,201	21 Feb 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CTKB	Restricted Stock Units	Options Exercise	$0	-1,752	-7.9%	$0.000000	20,450	21 Feb 2023	Common Stock	1,752		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F2	Represents the number of shares withheld by and surrendered to the Issuer on February 21, 2023, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
F3	The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.